Eledon Pharmaceuticals
The patient was treated in the procedure, conducted at Mass General Transplant Center and in collaboration with partner eGenesis, and was recently released from the hospital. 

Today,  February 07, 2025, Eledon Pharmaceuticals (ELDN) announced that tegoprubart, its investigational anti-CD40L antibody, was used as a key component of the immunosuppression therapy regimen in a patient who recently received . . .